View allAllogeneic Cell SourcingCell Collection NetworkCell Therapy Supply ChainClinical Trials SupportIndustry StandardizationOutcomes ReportingSales Sheets
Sort by dateSort by name
DescendingAscending
Webinar

When does outsourcing autologous collection center qualification and the cell therapy supply chain make sense?

Allogeneic Cell Sourcing, Cell Collection Network, Clinical Trials Support, Industry Standardization

View Webinar The first autologous CAR-T therapy was approved in 2017, and the industry has since gained substantial operating experience, treating tens of thousands of patients globally. Some drug sponsors have developed in-house teams to manage, improve, and maintain the infrastructure needed for these complex therapies, while others have opted to outsource these responsibilities. The…

Webinar

Understanding and leveraging cord blood bank capabilities and practices in cell therapy development

Allogeneic Cell Sourcing, Cell Collection Network, Clinical Trials Support, Industry Standardization

View Webinar The cord blood banking industry has been around for over 30 years, focusing on acquiring units for use in hematopoietic stem cell transplant. Recent research indicates that cord blood can be a valuable source of naïve cells for cell therapy manufacturing. Cord blood banks are evolving their processes to accommodate the use of…

Webinar

Optimizing Access to High-Quality, Standardized and Compliant Leukopaks for the Development and Commercialization of Allogeneic Therapies

Allogeneic Cell Sourcing, Cell Collection Network, Clinical Trials Support, Industry Standardization

View Webinar Cellular starting material is the most critical component in the allogeneic cell therapy manufacturing process. Ensuring material access while maintaining quality, consistency and regulatory compliance are necessary throughout every stage of clinical development through commercialization. During this webinar, you will learn about: Factors to ensure streamlined access to high-quality, consistent starting material for…

Webinar

The role of AI in predicting stem cell donor availability

Clinical Trials Support, Outcomes Reporting

View Webinar For allogeneic cell therapy developers, donor availability is a critical factor. Without a donor, there is no therapy. Watch this webinar to learn how groundbreaking AI-based approaches, like the NMDPSM Donor Readiness Score, can predict the availability of every registered donor and evaluate the predictive power during donor selection.  Our expert panel will explain how to:…

Case Study

How Cell Therapy Clinical Trials Can Save Time and Cost

Allogeneic Cell Sourcing, Clinical Trials Support

A client initiated a Phase I clinical trial for its allogeneic cell therapy. Several months in, limited success recruiting patients had led to an expensive lack of progress. The client engaged with the CIBMTR® Bioinformatics Consulting team through NMDP BioTherapies℠ to identify U.S. states and counties with the highest density of patients and donors with…

Webinar

How Patient Focus Drives Clinical Trial Results: The Intersection of Sponsor, CRO, Site and Patient.

Clinical Trials Support, Outcomes Reporting

Clinical trial sponsors and CROs have compelling reasons to design an effective clinical trial. You need to not only to answer your research question but also mitigate budget pressures and quickly bring a product to market that addresses patients’ chief complaints. In this webinar you’ll walk away with a better understanding of: Why the voice…

Clinical Trials Support

Comprehensive Clinical Trial Support

Clinical Trials Support

Cell therapy clinical trials—including those for hematopoietic cell transplantation (HCT)—come with unique challenges and complexity that impact the clinical trial sponsor, investigators, clinical trial sites, physicians, and patients and their caregivers. We offer comprehensive clinical trial services for academic and industry investigators and sponsors, as well as patients, because we know saving more lives through…